Afobam

Afobam may be available in the countries listed below.

Ingredient matches for Afobam

Alprazolam

Alprazolam is reported as an ingredient of Afobam in the following countries:

• Poland

International Drug Name Search

Euglucon

Euglucon may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Euglucon

Glibenclamide

Glibenclamide is reported as an ingredient of Euglucon in the following countries:

• Belgium


• Croatia (Hrvatska)


• Germany


• Italy


• Japan


• Peru


• Slovenia


• Spain


• United Kingdom

International Drug Name Search

Mixtard 50 HM

Mixtard 50 HM may be available in the countries listed below.

Ingredient matches for Mixtard 50 HM

Insulin Injection, Biphasic Isophane

Insulin Injection, Biphasic Isophane human (a derivative of Insulin Injection, Biphasic Isophane) is reported as an ingredient of Mixtard 50 HM in the following countries:

• Bangladesh

International Drug Name Search

Coretec

Coretec may be available in the countries listed below.

Ingredient matches for Coretec

Olprinone

Olprinone hydrochloride monohydrate (a derivative of Olprinone) is reported as an ingredient of Coretec in the following countries:

• Japan

International Drug Name Search

Alfaciclina

Alfaciclina may be available in the countries listed below.

Ingredient matches for Alfaciclina

Tetracycline

Tetracycline hydrochloride (a derivative of Tetracycline) is reported as an ingredient of Alfaciclina in the following countries:

• Venezuela

International Drug Name Search

Dihydrocodeine, Aspirin and Caffeine

Dosage Form: capsule
Dihydrocodeine bitartrate and aspirin and caffeine

Dihydrocodeine, Aspirin and Caffeine Description

Each capsule contains 16 mg drocode (dihydrocodeine) bitartrate (Warning–may be habit-forming), 356.4 mg aspirin, and 30 mg caffeine.


The inactive ingredients present are alginic acid, cellulose, D&C Red 28, FD&C Blue 1, gelatin, iron oxides, stearic acid, and titanium dioxide.

Dihydrocodeine, Aspirin and Caffeine - Clinical Pharmacology

Dihydrocodeine is a semisynthetic narcotic analgesic, related to codeine, with multiple actions qualitatively similar to those of codeine; the most prominent of these involve the central nervous system and organs with smooth-muscle components. The principal action of therapeutic value is analgesia.

The capsule also contains the nonnarcotic antipyretic-analgesic, aspirin.

Indications and Usage for Dihydrocodeine, Aspirin and Caffeine

For the relief of moderate to moderately severe pain.

Contraindications

Hypersensitivity to dihydrocodeine, codeine, or aspirin.

Warnings

Salicylates should be used with extreme caution in the presence of peptic ulcer or coagulation abnormalities.

Drug Dependence

Dihydrocodeine can produce drug dependence of the codeine type and therefore has the potential of being abused. Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of dihydrocodeine, and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic-containing medications. Like other narcotic-containing medications, dihydrocodeine is subject to the provisions of the Federal Controlled Substances Act.

Usage in Ambulatory Patients

Dihydrocodeine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a car or operating machinery. The patient using the dihydrocodeine bitartrate, aspirin, and caffeine capsule should be cautioned accordingly.

Interactions with other Central Nervous System Depressants

Patients receiving other narcotic analgesics, general anesthetics, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) concomitantly with the dihydrocodeine bitartrate, aspirin, and caffeine capsule may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced.

Usage in Pregnancy

Reproduction studies have not been performed in animals. There is no adequate information on whether this drug may affect fertility in human males and females or has a teratogenic potential or other adverse effect on the fetus.

Usage in Children

Preparations containing aspirin should be kept out of the reach of children. The dihydrocodeine bitartrate, aspirin, and caffeine capsule is not recommended for patients 12 years of age and under. Since there is no experience in chil­dren who have received this drug, safety and efficacy in children have not been established.

Precautions

The dihydrocodeine bitartrate, aspirin, and caffeine capsule should be given with caution to certain patients, such as the elderly or debilitated.

Drug Interactions

The CNS-depressant effects of the dihydrocodeine bitartrate, aspirin, and caffeine capsule may be additive with that of other CNS depressants. See “WARNINGS.”

Aspirin may enhance the effects of anticoagulants and inhibit the uricosuric effects of uricosuric agents.

Geriatric Use

Clinical studies of the dihydrocodeine bitartrate, aspirin, and caffeine capsule did not include sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects.

In general, dose selection for an elderly patient should be cautious, starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Adverse Reactions

The most frequently observed reactions include lightheadedness, dizziness, drowsiness, sedation, nausea, vomiting, constipation, pruritus, and skin reactions.

Dihydrocodeine, Aspirin and Caffeine Dosage and Administration

Dosage should be adjusted according to the severity of the pain and the response of the patient. The dihydrocodeine bitartrate, aspirin, and caffeine capsule is given orally. The usual adult dose is two capsules every 4 hours as need­ed for pain.

How is Dihydrocodeine, Aspirin and Caffeine Supplied

Dihydrocodeine bitartrate, aspirin, and caffeine Capsules are blue and gray, marked “CP” and “419”, supplied in:

Bottles of 100 capsules; NDC 57902-419-88

 

Store at room temperature, approx. 25°C (77°F). Keep tightly closed.

 

Dispense in tight container.

Manufactured for and distributed by:

EUSA Pharma (USA), Inc.

One Summit Square, Suite 201

1717 Langhorne Newtown Rd.

Langhorne, PA 19047
www.eusapharma.com

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 57902-419-88

100 Capsules

Dihydrocodeine bitartrate, aspirin, and caffeine capsules

Each capsule contains: 16 mg drocode (dihydrocodeine) bitartrate (Warning–may

be habit-forming), 356.4 mg aspirin, and 30 mg caffeine.

SEALED FOR YOUR PROTECTION

Rx Only

EUSA Pharma (USA), Inc.

DIHYDROCODEINE BITARTRATE AND ASPIRIN AND CAFFEINE  DC dihydrocodeine bitartrate and aspirin and caffeine  capsule

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 57902-419 (49708-419) Route of Administration ORAL DEA Schedule CIII

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength DIHYDROCODEINE BITARTRATE (DIHYDROCODEINE) DIHYDROCODEINE BITARTRATE 16 mg ASPIRIN (ASPIRIN) ASPIRIN 356.4 mg CAFFEINE (CAFFEINE) CAFFEINE 30 mg

Inactive Ingredients Ingredient Name Strength ALGINIC ACID   POWDERED CELLULOSE   D&C RED NO. 28   FD&C BLUE NO. 1   GELATIN   FERROSOFERRIC OXIDE   STEARIC ACID   TITANIUM DIOXIDE

Product Characteristics Color BLUE, GRAY Score no score Shape CAPSULE Size 19mm Flavor Imprint Code CP;419 Contains

Packaging # NDC Package Description Multilevel Packaging 1 57902-419-88 100 CAPSULE In 1 BOTTLE None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA011483	04/25/2011

Labeler - EUSA Pharma (USA), Inc. (038596862)

Revised: 04/2011EUSA Pharma (USA), Inc.

More Dihydrocodeine, Aspirin and Caffeine resources

• Dihydrocodeine, Aspirin and Caffeine Side Effects (in more detail)
• Dihydrocodeine, Aspirin and Caffeine Use in Pregnancy & Breastfeeding
• Dihydrocodeine, Aspirin and Caffeine Drug Interactions
• Dihydrocodeine, Aspirin and Caffeine Support Group
• 0 Reviews for Dihydrocodeine, Aspirin and Caffeine - Add your own review/rating

Compare Dihydrocodeine, Aspirin and Caffeine with other medications

• Pain

B-COL

B-COL may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for B-COL

Colistin Sulfate

Colistin sulfate (a derivative of Colistin) is reported as an ingredient of B-COL in the following countries:

• Switzerland

International Drug Name Search

Lollarm

Lollarm may be available in the countries listed below.

Ingredient matches for Lollarm

Flavoxate

Flavoxate hydrochloride (a derivative of Flavoxate) is reported as an ingredient of Lollarm in the following countries:

• Japan

International Drug Name Search

Lorson

Lorson may be available in the countries listed below.

Ingredient matches for Lorson

Dexamethasone

Dexamethasone is reported as an ingredient of Lorson in the following countries:

• Indonesia

Dexchlorpheniramine

Dexchlorpheniramine maleate (a derivative of Dexchlorpheniramine) is reported as an ingredient of Lorson in the following countries:

• Indonesia

International Drug Name Search

Advovet suini

Advovet suini may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Advovet suini

Danofloxacin

Danofloxacin mesilate (a derivative of Danofloxacin) is reported as an ingredient of Advovet suini in the following countries:

• Italy

International Drug Name Search

Bergagyn

Bergagyn may be available in the countries listed below.

Ingredient matches for Bergagyn

Benzalkonium Chloride

Benzalkonium chloride (a derivative of Benzalkonium) is reported as an ingredient of Bergagyn in the following countries:

• Italy

International Drug Name Search

Glynase

In the US, Glynase (glyburide systemic) is a member of the drug class sulfonylureas and is used to treat Diabetes, Type 2.

US matches:

• Glynase Tablets (Micronized)


• Glynase PresTab


• Glynase Pres-Tab


• Glynase

Ingredient matches for Glynase

Glibenclamide

Glibenclamide is reported as an ingredient of Glynase in the following countries:

• Bahrain


• Oman


• United States

Glipizide

Glipizide is reported as an ingredient of Glynase in the following countries:

• India


• Myanmar


• Sri Lanka

International Drug Name Search

Ritomune

Ritomune may be available in the countries listed below.

Ingredient matches for Ritomune

Ritonavir

Ritonavir is reported as an ingredient of Ritomune in the following countries:

• Georgia


• India

International Drug Name Search

Aciclosina

Aciclosina may be available in the countries listed below.

Ingredient matches for Aciclosina

Acyclovir

Aciclovir is reported as an ingredient of Aciclosina in the following countries:

• Portugal

International Drug Name Search

Prazole

Prazole may be available in the countries listed below.

Ingredient matches for Prazole

Omeprazole

Omeprazole is reported as an ingredient of Prazole in the following countries:

• Bangladesh

International Drug Name Search

Deprizine

ranitidine hydrochloride

Dosage Form: kit for oral suspension
Deprizine

Principal Display Panel

Do not use if safety seal is broken

NDC 43093-102-01

Rx only

FusePaq™  Compounding Kit for Oral Suspension

Deprizine™

(ranitidine hydrochloride 16.8 mg/mL [15 mg/mL ranitidine], in oral suspension - compounding kit)

Description:

This kit contains active and inactive bulk materials to compound a ranitidine hydrochloride oral suspension. The instructions describe how to prepare 250 mL of a compounded oral suspension containing 16.8 mg/mL ranitidine hydrochloride (15 mg/mL as ranitidine). Other concentrations are possible. Exact strength of compounded suspension must be defined by the prescriber.

Active Ingredient:

• 4.2 g ranitidine hydrochloride, USP

Inactive Ingredients:

• 250 mL oral suspension vehicle (water, glycerin, L-glutamine, xylitol, monoammonium glycyrrhizinate, pineapple flavor, xanthan gum, stevia powder, orange flavor, sodium citrate, citric acid, potassium sorbate, sodium benzoate)


• Press-in bottle adaptor for oral dispenser


• Oral dispenser


• Instructions
  

For Prescription Compounding Only

U.S. Patents Pending

CS38-A1 rev 1

Drug Label

Do not use if safety seal is broken

For Prescription Compounding Only

Ranitidine Hydrochloride

1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]-methyl]thio]ethyl]-N'-methyl-2-nitro-, monohydrochloride

CAS# 66357-59-3

Net contents: 4.2 g

Repackaged by:

Fusion Pharmaceuticals, LLC

Camarillo, CA 93012

CS35-A1 rev 0

Suspension Label

Do not use if safety seal is broken

For Prescription Compounding Only

Oral Suspension Vehicle

Sugar, dye, and paraben free

Ingredients: water, glycerin, L-glutamine, xylitol, monoammonium glycyrrhizinate, pineapple flavor, xanthan gum, stevia powder, orange flavor, citric acid, sodium citrate, potassium sorbate, sodium benzoate

Net Contents: 250 mL (8.4 fl oz)

Manufactured for:

Fusion Pharmaceuticals LLC

Camarillo, CA 93012

CS36-A1 rev 0

Instructions Insert

NDC 43093-102-01

Rx only

FusePaq™

Deprizine™

(ranitidine hydrochloride 16.8 mg/mL [15 mg/mL ranitidine], in oral suspension - compounding kit)

FusePaq™ compounding kits provide a convenient approach to rapidly compound prescription medications, as all components are pre-measured. This kit is manufactured according to US FDA current Good Manufacturing Practice (cGMP).

For Prescription Compounding Only

Description:


This kit contains active and inactive bulk materials to compound a ranitidine hydrochloride oral suspension. These instructions describe how to prepare 250 mL of a compounded oral suspension containing 16.8 mg/mL ranitidine hydrochloride (15 mg/mL as ranitidine). Other concentrations are possible. Exact strength of compounded suspension must be defined by the prescriber.

Contents:

• 4.2 g ranitidine hydrochloride, USP


• 250 mL oral suspension vehicle (water, glycerin, L-glutamine, xylitol, monoammonium glycyrrhizinate, pineapple flavor, xanthan gum, stevia powder, orange flavor, citric acid, sodium citrate, potassium sorbate, sodium benzoate)


• Press-in bottle adaptor for oral dispenser


• Oral dispenser


• Instructions

Instructions for Compounding

Ranitidine hydrochloride, 16.8 mg/mL (15 mg/mL as ranitidine) oral suspension

1    Remove and Inspect the Contents of the Kit


Ensure that the safety seals are present and intact on the ranitidine hydrochloride and oral suspension vehicle bottles. If the seals are not intact, do not use the kit.

2    Prepare for Mixing


Wear gloves and eye protection during compounding operations. Remove the seal from the oral suspension bottle. Break the perforated seal and remove the cap from the ranitidine hydrochloride bottle.

3    Transfer Ranitidine Hydrochloride to the Suspension Bottle


Uncap the suspension bottle. Pour a small amount of suspension liquid (approximately one-third to one-half the volume of the ranitidine hydrochloride bottle) into the ranitidine hydrochloride bottle. Cap the ranitidine hydrochloride bottle and shake well several times to dissolve the ranitidine hydrochloride powder. Empty the contents into the suspension bottle. Cap and mix the suspension bottle. Repeat this step 3 times. Visually ensure that all of the ranitidine hydrochloride has been dissolved and transferred to the suspension bottle.

4    Complete the Mixing Process


Insert the press-in bottle adaptor into the suspension bottle. Recap the suspension bottle. Mix well by inverting repeatedly several times.

5    Re-label the Compounded Suspension


Label the compounded suspension per the pharmacy's standard practice. Remove or obscure the oral suspension vehicle label, since the label is no longer accurate once compounding is completed.

Store the unused kit at room temperature of 15-30°C (59-86°F). Once prepared, store the mixed suspension between 2-8°C (36-46°F) . The compounded suspension is stable for at least eight weeks when stored under refrigeration, based upon real-time and accelerated stability studies.

Each lot of suspension vehicle is tested to meet microbial limits per USP Microbial Limit Test <61>. In addition, the suspension vehicle formulation has passed the USP <51> Antimicrobial Effectiveness Test.


An oral dispenser is provided in the kit and may be used to facilitate delivery of the suspension.

U.S. Patents Pending

Manufactured by:

Fusion Pharmaceuticals LLC

768 Calle Plano

Camarillo, CA 93012

CS43-A1 rev 1

Deprizine  ranitidine hydrochloride  kit

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 43093-102

Packaging # NDC Package Description Multilevel Packaging 1 43093-102-01 1 KIT In 1 KIT None

QUANTITY OF PARTS Part # Package Quantity Total Product Quantity Part 1 1 BOTTLE, GLASS   4.2 g Part 2 1 BOTTLE, PLASTIC   250 mL

Part 1 of 2 RANITIDINE HYDROCHLORIDE  ranitidine hydrochloride  powder, for suspension

Product Information       Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Ranitidine Hydrochloride (Ranitidine) Ranitidine Hydrochloride 4.2 g  in 4.2 g

Inactive Ingredients Ingredient Name Strength No Inactive Ingredients Found

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 4.2 g In 1 BOTTLE, GLASS None

Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other 02/08/2010

Part 2 of 2 ORAL SUSPENSION VEHICLE  suspension  liquid

Product Information       Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength No Active Ingredients Found

Inactive Ingredients Ingredient Name Strength Water   Glycerin   Glutamine   Xylitol   GLYCYRRHIZIN, AMMONIATED   Pineapple   Xanthan Gum   Stevia Leaf   Orange   Citric Acid   Sodium Citrate   Potassium Sorbate   Sodium Benzoate

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 250 mL In 1 BOTTLE, PLASTIC None

Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other 02/08/2010

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		02/08/2010

Labeler - Fusion Pharmaceuticals LLC (021420944)

Establishment
Name	Address	ID/FEI	Operations
Fusion Pharmaceuticals LLC		021420944	manufacture

Revised: 02/2010Fusion Pharmaceuticals LLC

More Deprizine resources

• Deprizine Side Effects (in more detail)
• Deprizine Use in Pregnancy & Breastfeeding
• Deprizine Drug Interactions
• Deprizine Support Group
• 0 Reviews for Deprizine - Add your own review/rating

Compare Deprizine with other medications

• Duodenal Ulcer
• Duodenal Ulcer Prophylaxis
• Erosive Esophagitis
• Gastric Ulcer Maintenance Treatment
• Gastrointestinal Hemorrhage
• GERD
• Indigestion
• Pathological Hypersecretory Conditions
• Stomach Ulcer
• Stress Ulcer Prophylaxis
• Surgical Prophylaxis
• Zollinger-Ellison Syndrome

Ferridon

Ferridon may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Ferridon

Iron Dextran

Iron Dextran is reported as an ingredient of Ferridon in the following countries:

• Netherlands

International Drug Name Search